Opinion|Videos|July 29, 2024
Out of Pocket Costs Associated with Biosimilar Use
The panel discusses out of pocket costs and the impact of the 340b program for various patient types.
Advertisement
Episodes in this series
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
5 FAQs: Ebola Outbreaks and the Challenge of Public Trust
2
How Hospital Specialty Pharmacies Are Closing the Pharmacy Desert Gap
3
Targeting Oxidative Stress Could Fill a Gap in the Vitiligo Treatment Toolbox
4
How Healthy Gut Microbiota Can Give CAR T-Cell Recipients a Leg Up
5